This website uses cookies
Read our Privacy policy and Terms of use for more information.
CV
+2

Apr 4, 2026
•
16 min read
Here's what the evidence actually says — and why I stopped waiting for symptoms before acting on it.

CV
+2

Apr 1, 2026
•
17 min read
New guidelines. New trials. The same conclusion. The deniers didn't get the memo.

GLP1
+3

Mar 27, 2026
•
15 min read
It's not the injection site. It's not gut GLP-1. It's not thermogenesis. The pharmacokinetics of semaglutide across multiple trials offer a surprisingly clean window into how this molecule — and this biology — actually works.

GLP1
+2

Mar 25, 2026
•
12 min read
The Definitive GLP-1 Travel Guide — TSA, Storage, Dosing, and Everything In Between

GLP1
+2

Mar 21, 2026
•
13 min read
A new BMJ Medicine analysis quantifies what happens to cardiovascular risk after GLP-1 discontinuation. The numbers are striking. The framing some are applying to them is wrong.

GLP1
+3

Mar 19, 2026
•
14 min read
Retatrutide may be the first pharmacotherapy to approach bariatric surgery–level weight loss. Phase 3 data now confirm what phase 2 only suggested: this is a categorically different molecule.
